Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 1

Conditions

Hypertension

Treatments

Drug: Comparator: Candesartan cilexetil
Drug: Comparator: Pbo
Drug: MK-5478

Study type

Interventional

Funder types

Industry

Identifiers

NCT01025843
5478-001
2009-016048-38 (EudraCT Number)

Details and patient eligibility

About

This is a two part introductory clinical trial with MK-5478. Part I will evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of MK-5478 in young, healthy males. Part II will evaluate the safety, tolerability and pharmacodynamic effects of MK-5478 in participants with hypertension. The primary hypothesis is that single oral doses of MK-5478 are sufficiently safe and well tolerated.

Enrollment

20 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Part I:

  • Is a male between 18 to 50 years of age
  • Is in good health
  • Is a non-smoker

Part II:

  • Is male of non-child bearing potential between 18 and 50 years of age
  • Has hypertension (high blood pressure)

Exclusion criteria

Part I and Part II:

  • Has a history of stroke, seizures or major neurological disorder
  • Has a history of cancer
  • Has a history of any cardiovascular disease
  • Is unable to refrain from the use of any prescription or non-prescription drugs
  • Consumes excessive amounts of alcohol or caffeine
  • Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

20 participants in 10 patient groups

Pbo → 5 mg → Candesartan → 24 mg → 38 mg
Experimental group
Description:
Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
1 mg → 5 mg → 12 mg → Candesartan → Pbo
Experimental group
Description:
1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
1 mg → Candesartan → Pbo → 24 mg → 38 mg
Experimental group
Description:
1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
1 mg → 5 mg → 12 mg → Pbo → Candesartan
Experimental group
Description:
1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan
Experimental group
Description:
Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
2 mg→Pbo → Candesartan → Pbo fed→38 mg
Experimental group
Description:
2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
2 mg→Candesartan→Pbo→Candesartan fed→38 mg
Experimental group
Description:
2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
2 mg → 8 mg → 18 mg → 2 mg fed → Pbo
Experimental group
Description:
2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
Candesartan→8 mg→ 18 mg →2 mg fed→38 mg
Experimental group
Description:
Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil
Candesartan→Pbo → 12 mg → 24 mg→38 mg
Experimental group
Description:
Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Treatment:
Drug: MK-5478
Drug: Comparator: Pbo
Drug: Comparator: Candesartan cilexetil

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems